27.50
price up icon15.50%   3.69
pre-market  Pre-market:  26.98   -0.52   -1.89%
loading
Instil Bio Inc stock is traded at $27.50, with a volume of 596.59K. It is up +15.50% in the last 24 hours and down -8.03% over the past month. Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
See More
Previous Close:
$23.81
Open:
$24.25
24h Volume:
596.59K
Relative Volume:
2.40
Market Cap:
$246.42M
Revenue:
-
Net Income/Loss:
$-74.14M
P/E Ratio:
-2.4144
EPS:
-11.39
Net Cash Flow:
$-65.70M
1W Performance:
+24.04%
1M Performance:
-8.03%
6M Performance:
+33.43%
1Y Performance:
+169.08%
1-Day Range:
Value
$23.15
$30.90
1-Week Range:
Value
$20.60
$30.90
52-Week Range:
Value
$9.6201
$92.00

Instil Bio Inc Stock (TIL) Company Profile

Name
Name
Instil Bio Inc
Name
Phone
(972) 499-3350
Name
Address
3963 MAPLE AVENUE, DALLAS
Name
Employee
14
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
TIL's Discussions on Twitter

Compare TIL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TIL
Instil Bio Inc
27.50 246.42M 0 -74.14M -65.70M -11.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Instil Bio Inc Stock (TIL) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-07-25 Upgrade Jefferies Hold → Buy
Nov-04-24 Initiated JMP Securities Mkt Perform
Apr-12-24 Downgrade Jefferies Buy → Hold
Nov-01-22 Downgrade Cowen Outperform → Market Perform
Nov-01-22 Downgrade Truist Buy → Hold
Aug-13-21 Initiated Robert W. Baird Outperform
Apr-13-21 Initiated Cowen Outperform
Apr-13-21 Initiated Morgan Stanley Equal-Weight
Apr-13-21 Initiated Truist Buy
View All

Instil Bio Inc Stock (TIL) Latest News

pulisher
Jun 17, 2025

Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet - MSN

Jun 17, 2025
pulisher
Jun 11, 2025

Instil Bio (TIL) Enhances Axion Bio Board with New Appointment | - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Instil Bio Names John Maraganore, Ph.D., to Board Role - GlobeNewswire

Jun 11, 2025
pulisher
Jun 11, 2025

Instil Bio Names John Maraganore, Ph.D., To Board - citybiz

Jun 11, 2025
pulisher
Jun 11, 2025

Instil Bio, Inc. Announces the Addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Its Wholly-Owned Subsidiary - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program - Yahoo Finance

Jun 11, 2025
pulisher
Jun 06, 2025

(TIL) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 06, 2025
pulisher
Jun 05, 2025

Instil Bio Appoints ‘Seasoned’ Biopharma Exec as Chief Medical Officer - Dallas Innovates

Jun 05, 2025
pulisher
Jun 05, 2025

H.C. Wainwright reiterates Instil Bio stock Buy rating amid partnership news By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Instil Bio (TIL) Receives Reiterated Buy Rating from HC Wainwrig - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

H.C. Wainwright reiterates Instil Bio stock Buy rating amid partnership news - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

Instil Bio (TIL) Receives Reiterated Buy Rating from HC Wainwright & Co. | TIL Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 04, 2025

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice - Yahoo Finance

Jun 04, 2025
pulisher
Jun 03, 2025

Instil Bio appoints new Chief Medical Officer By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

Instil Bio (TIL) Rating Reiterated as Market Perform by JMP Secu - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Instil Bio (TIL) Rating Reiterated as Market Perform by JMP Securities | TIL Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Instil Bio (TIL) Appoints Jamie Freedman as Chief Medical Officer - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Instil Bio (TIL) Appoints Jamie Freedman as Chief Medical Officer | TIL Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Instil Bio appoints new Chief Medical Officer - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Former Genentech Executive With 15 FDA Approvals Joins Instil Bio to Accelerate Cancer Drug Development - Stock Titan

Jun 02, 2025
pulisher
Jun 02, 2025

Instil Bio shares hold as JMP reiterates Market Perform rating By Investing.com - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

Instil Bio shares hold as JMP reiterates Market Perform rating - Investing.com Australia

Jun 02, 2025
pulisher
May 31, 2025

Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock? - MSN

May 31, 2025
pulisher
May 30, 2025

Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade - MSN

May 30, 2025
pulisher
May 30, 2025

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times

May 30, 2025
pulisher
May 30, 2025

Instil Bio CEO Reveals Latest Pipeline Updates at Prestigious Jefferies Healthcare Conference - Stock Titan

May 30, 2025
pulisher
May 28, 2025

Instil Bio Elects Director and Ratifies Auditor - TipRanks

May 28, 2025
pulisher
May 28, 2025

What's Behind The Big Stock Moves? SPRO, TIL, IMAB.... - Nasdaq

May 28, 2025
pulisher
May 27, 2025

Instil Bio Advances Phase 2 Trial in China - TipRanks

May 27, 2025
pulisher
May 26, 2025

(TIL) Proactive Strategies - news.stocktradersdaily.com

May 26, 2025
pulisher
May 25, 2025

Instil Bio: Second Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success (TIL) - Seeking Alpha

May 25, 2025
pulisher
May 24, 2025

H.C. Wainwright lifts Instil Bio stock target to $125 By Investing.com - Investing.com South Africa

May 24, 2025
pulisher
May 24, 2025

H.C. Wainwright lifts Instil Bio stock target to $125 - Investing.com

May 24, 2025
pulisher
May 24, 2025

Instil Bio (TIL) Receives Price Target Upgrade by HC Wainwright & Co. | TIL Stock News - GuruFocus

May 24, 2025
pulisher
May 24, 2025

H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following P - GuruFocus

May 24, 2025
pulisher
May 23, 2025

Instil Bio and ImmuneOnco to Host Investor and Analyst - GlobeNewswire

May 23, 2025
pulisher
May 23, 2025

Instil Bio and ImmuneOnco Announce Joint Investor Breakfast in Chicago to Discuss Immuno-Oncology Developments - Nasdaq

May 23, 2025
pulisher
May 23, 2025

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving ... - Bluefield Daily Telegraph

May 23, 2025
pulisher
May 23, 2025

H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following Positive Data Release | TIL Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago - GlobeNewswire

May 23, 2025
pulisher
May 22, 2025

Instil Bio (TIL) Advances Clinical Trials for NSCLC Treatment | - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in - GlobeNewswire

May 22, 2025

Instil Bio Inc Stock (TIL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Cap:     |  Volume (24h):